GLP-1 Injection Technique: Site Rotation & Pen Handling

What the injection actually is

GLP-1 receptor agonists are given as a subcutaneous injection, which means into the fatty tissue just under the skin rather than into muscle. The needle is short, typically 4 to 8 millimeters, and the volume is small, usually well under one milliliter. The medication is supplied either in a single-dose disposable pen (Wegovy®, Zepbound®) or a multi-dose pen with a dial (Ozempic®, Mounjaro®). Each manufacturer publishes a stepwise instructions-for-use guide; what follows is the general pattern, not a substitute for that document.

Where to inject

The three approved sites for GLP-1 medications are the abdomen, the front of the thigh, and the back of the upper arm. The abdomen is preferred by most patients because it is easy to see and reach, and the subcutaneous layer is consistent. Stay at least five centimeters from the navel and avoid areas with scars, stretch marks, or visible bruising.

For the thigh, the target zone is the outer or front surface of the upper leg, roughly hand-width below the hip and hand-width above the knee. For the arm, the back of the upper arm midway between the shoulder and elbow is the standard site; this one usually requires another person to inject for you.

Site rotation

Repeating the same injection site week after week causes lipohypertrophy, a thickening of the subcutaneous tissue that looks like a soft lump and that absorbs the medication less reliably. Once lipohypertrophy develops it can take months to resolve and may permanently dull the response to that area.

The standard rotation strategy is to divide the abdomen into quadrants, rotate week to week through them, and within each quadrant stay at least one inch away from the previous spot. A simple log, paper or in an app, prevents the unconscious tendency to land in the same comfortable spot repeatedly. Switching between abdomen and thigh every few weeks is also reasonable.

Pen handling and preparation

Pens should be stored in the refrigerator between 2 and 8 degrees Celsius until first use. After first use, most pens can be kept at room temperature below 30 degrees Celsius for a defined number of weeks, which differs by product. Check the specific prescribing information for the exact window. Do not freeze the pen, and discard it if it has been frozen.

Many patients prefer to take the pen out of the refrigerator 15 to 30 minutes before injection so the medication is closer to room temperature, which reduces the stinging that cold liquid causes. Inspect the cartridge for clarity. If the liquid looks cloudy or contains particles, do not use it.

Each pen requires a new disposable needle. Attach the needle, prime the pen following the manufacturer's specific procedure (the steps vary), and verify that a small drop appears at the needle tip. Priming clears air from the needle and confirms the pen is delivering.

The injection itself

Clean the skin with an alcohol wipe and let it dry fully. Injecting through still-wet alcohol stings more. Pinch a fold of skin if the device's instructions call for it; some auto-injector pens are designed to be pressed flat against the skin without pinching. Insert the needle at a 90-degree angle for most pens. Depress the plunger or activation button and hold for the count specified in the instructions, usually five or ten seconds, before withdrawing. Holding the pen in place ensures the full dose is delivered rather than dribbling back out as the needle is removed.

Mild bleeding or a small bruise can occur and does not affect dosing. Do not rub the site. A drop of blood can be blotted with gauze.

Sharps disposal

Used pens and needles are biohazardous sharps and should not go in household trash or recycling. The FDA recommends a rigid, puncture-resistant container with a tight lid, labeled as sharps, and disposed of through a state or municipal program. Many pharmacies accept sharps containers for disposal. Improvised containers like detergent bottles can substitute in a pinch but are not the formal recommendation.

Missed doses

The handling of a missed dose depends on the product. For weekly semaglutide and tirzepatide, the general rule is to take the missed dose within a defined number of days from the scheduled day, and otherwise skip it. The prescribing information for each product gives the specific window. Do not double up to make up for a missed dose. A consistent weekly schedule, anchored to a fixed day, makes missed doses less likely.

When to seek medical advice

Persistent or expanding redness, warmth, swelling, or pain at an injection site beyond a day or two suggests infection and should be evaluated. Hives, facial swelling, difficulty breathing, or other signs of severe allergic reaction after any dose require emergency care. A hard, persistent lump that does not resolve over weeks may be lipohypertrophy and is worth showing to the prescriber.

---

Wegovy®, Ozempic®, Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® are trademarks of Eli Lilly and Company. PepAI is independent.